Vida Ventures ("Vida"), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a ...

Aktis Oncology Inc. shares jumped 24 percent in their trading debut after the clinical-stage biotechnology company raised ...

Cancer drug developer Aktis Oncology said on Thursday it priced its upsized U.S. initial public offering at $18 per share, ...

No IPOs are currently scheduled in the week ahead, although smaller issuers may join the calendar throughout the week. Read ...

Clinical-stage biotech Aktis Oncology (AKTS), which counts Eli Lilly (LLY) among its partners, traded sharply higher after ...

Aktis Oncology, Inc. targets $200M IPO to advance radiopharmaceuticals for solid tumors. Click for more on the upcoming AKTS ...

Aktis Oncology is seeking a valuation of as much as $840 million in its U.S. initial public offering, the biotechnology ...

Aktis Oncology Inc., a clinical-stage biotechnology company focused on using so-called radiopharmaceuticals for treatments, ...

Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized ...

Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not ...